Sanofi-Aventis U.S., LLC v. Fresenius Kabi USA, LLC, No. 18-1804 (Fed. Cir. Aug. 14, 2019)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Plaintiffs-Appellants (collectively, “Sanofi”) appeal from the judgment of the U.S. District Court for the Dis- trict of New Jersey holding , after a bench trial, claims 7, 11, 14–16, and 26 of U.S. Patent 8,927,592 (the “’592 pa- tent”) invalid as obvious. Sanofi-Aventis U.S. LLC v. Frese- nius Kabi USA, LLC , No. 14 -7869 (D.N.J. Dec. 19, 2017) (“Decision”). Defendants -Cross-Appellants (collectively, “Fresenius”) cross-appeal from the same judgment holding claims 1 and 2 of U.S. Patent 5,847,170 (the “’170 patent”) not invalid as obvious.